Navigation Links
Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
Date:2/19/2009

MINNEAPOLIS, Feb. 19 /PRNewswire/ -- Atritech, Inc. announced the upcoming presentation of the PROTECT AF trial results comparing the WATCHMAN(R) Left Atrial Appendage (LAA) Closure Device to the current standard of care, warfarin therapy, in patients with non-valvular atrial fibrillation. The results will be unveiled at the Late Breaking Clinical Trial session during the I2 Summit Scientific Meeting at 8:30 am on March 28, 2009. The I2 Summit is part of the Annual Meeting of the American College of Cardiology (ACC) being held March 28 - 31 in Orlando, Florida.

"This is a very important clinical study comparing the WATCHMAN to warfarin in the management of patients with atrial fibrillation. We are looking forward to the presentation by Dr. David Holmes, the Principal Investigator of the PROTECT AF Trial, at the ACC," remarked Jim Bullock, President and CEO. Hand-on demonstrations of the WATCHMAN technology will be available at the Atritech booth # 2857.

In August of 2008, Atritech announced the filing of its Pre-Market Approval Application (PMA) to the Food and Drug Administration (FDA). The PMA contained the results of the PROTECT AF Clinical Trial which began enrollment in early 2005. The WATCHMAN Device continues to be implanted in a limited number of sites while the product is under review at the FDA. To date over 70 devices have been implanted in the Continued Access Registry.

Atritech's WATCHMAN LAA Closure Technology is intended as an alternative to warfarin therapy for patients with non-valvular atrial fibrillation. Patients with atrial fibrillation (a heart condition which causes the upper chambers of the heart to beat too rapidly) are at a significantly greater risk of having a stroke due to embolization of clots that may form in the LAA. Typically these patients require blood thinning medications to prevent these clots from forming in the heart. Current medical therapy requires frequent monitoring and has diet and other drug interactions and increases the risk of bleeding. The WATCHMAN device may be an effective alternative to warfarin for these patients.

About Atritech

Atritech is privately held and based in Plymouth, Minnesota. Major investors in Atritech include SplitRock Partners, Prism Venture Partners, Tullis-Dickerson Partners, , The Vector Group, Thoma Cressey Funds, SightLine Funds and Affinity Capital. For more information, visit http://www.atritech.net.


'/>"/>
SOURCE Atritech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Atritech Announces Completion of a $22 Million Equity Financing
2. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
3. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
4. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
5. Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
6. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
7. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
8. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):